03/12/2021 - Institutional news
The Hospital del Mar Medical Research Institute (IMIM) has signed a five-year contract with the World Anti-Doping Agency (WADA, https://www.wada-ama.org/ ), within the framework of a tender of offers at an international level, worth € 1,880,000, for the preparation of reference materials for its external quality assessment program of laboratories (EQAS) accredited to carry out anti-doping control around the world (WADA's External Quality Assessment Scheme). Dr. Oscar Pozo, group leader of the Applied Metabolomics Research Group of the Neurosciences Research Program at IMIM, will be responsible for the execution of the contract as of January 2022.
02/12/2021 - Press release
A study using mice shows that animals fed a diet rich in beneficial live microorganisms suffer less from the addictive effects of alcohol consumption. The work has been published in the journal Frontiers in Nutrition. It is the first to analyse the possible relationship between intestinal bacteria and the possibility of altering addictive behaviours related to alcohol use. In the study, animals that maintain a healthy microbiota also avoid addiction relapse and have lesser effects from associated disorders such as depression and anxiety.
According to a study by the Hospital del Mar Medical Research Institute and the Germans Trias i Pujol Institute of Health Sciences published in the International Journal of Neuropsychopharmacology, driving after drinking alcohol mixed with energy drinks can give the driver a false sense of security, thus increasing the chances of driving while intoxicated and suffering an accident Due to their high caffeine content, energy drinks reduce the sedative effect of alcohol, despite not affecting its negative effects on driving ability Moreover, combining the two drinks increases blood concentrations of alcohol and caffeine. Researchers warn that these effects may favour alcohol intoxication in people with a lower tolerance to these drinks
Més informació "Mixing energy drinks with alcohol can increase the risk of a traffic accident"
21/10/2021 - General information
The Spanish Society of Epidemiology (SEE) in its XVII edition has awarded the "Prize for research by young researchers. Edition 2021: Miguel Carrasco" to Natàlia Soldevila-Domènech, predoctoral researcher of the Integrative Pharmacology and Systems Neuroscience research group at IMIM, for the project "Analysis of trajectories of cognition evaluated in a continuous manner with cognitive training tasks in older adults at risk of Alzheimer 's disease". The work aims to evaluate the feasibility, validity and reliability of a measure of cognition obtained from the performance on self?administered computerized cognitive training tasks, and to identify and characterize subgroups of elderly individuals following a similar cognitive trajectory during the course of a preventive intervention for cognitive decline (PENSA Study).
16/09/2021 - Press release
Older adults who are overweight or obese who stick most closely to the Mediterranean diet preserve their cognitive performance and even improve their abilities after three years, according to a study led by researchers at the Hospital del Mar Medical Research Institute and the CIBEROBN, published in the journal Clinical Nutrition. Memory improvements are proportional to the level of adherence to the Mediterranean diet, weight loss and increased physical activity. At the same time, these changes translate into improvements in people's quality of life. The work is based on the PREDIMED-PLUS trial and shows that women and people with less education gain less benefit on a cognitive level from this type of dietary intervention. This leads the researchers to support the personalization of these approaches in order to maximize the benefit.
Més informació "The Mediterranean diet helps improve cognitive function and memory"
05/05/2021 - General information
The General Assembly of the ISCIII Clinical Research Support Platform has elected Dr. Ana Aldea, Head of the Clinical Pharmacology Section at Hospital del Mar and coordinator of the IMIM Clinical Research Unit, as a member of the Steering Committee. The ISCIII Clinical Research Support Platform, (SCReN, Spanish Clinical Research Network), is a network structure supporting clinical research and is made up of the 34 units financed in the PT20 call of the Carlos III Health Institute, distributed among hospitals throughout the National Health System (SNS). This network structure, acting in a coordinated manner, will be responsible for executing the actions necessary to achieve the Platform's objectives.
28/04/2021 - General information
The head of the Epilepsy Unit at Hospital del Mar and coordinator of the Epilepsy Research Group at the Hospital del Mar Medical Research Institute has been appointed Spanish Society of Neurology representative in the field of epilepsy to the top European scientific body in the field of neurology.
12/03/2021 - General information
The head of Addictions Process at the Hospital del Mar Institute of Neuropsychiatry and Addictions (INAD) and coordinator of the Addictions research group at the Hospital del Mar Medical Research Institute has been recognised for her contribution to addictions research in Europe. Dr. Marta Torrens has be honoured with the EUFAS EAR 2020 Award, presented by theEuropean Federation of Addiction Societies and the journal European Addiction Research. This award recognises the work of the head of the INAD Addiction Process in terms of European research into addictions. The award has been presented since 2016 to figures who are outstanding in the field of addiction research. The awarding committee considered that the work of Dr. Torrens, with more than 200 high quality articles published in international journals, has made a substantial contribution to the advancement of translational research in this field, and has been instrumental in the introduction of various tools and scales for diagnosing and assessing dual pathology
21/03/2021 - General information
March 21st is World Down Syndrome Day and we are joining in by launching the "21 reasons to collaborate with science" campaign. The goal is to promote clinical research into people with Down's syndrome, to encourage them to get involved in the clinical studies that are currently being carried out and, in this way, to help improve the health and quality of life of these people. Through the 21 reasons campaign, the team of Dr. Rafael de la Torre, director of the Neurosciences research programme at the Hospital del Mar Medical Research Institute, wants to raise awareness and encourage people with Down syndrome to get involved in the studies they are conducting. According to Dr. de la Torre, "The therapeutic approach to these people, given their genetic features, has been quite specific, and the more knowledge we have, the more we will be able to adjust the therapy to their needs. Certain medical practices should also be studied in individuals with this syndrome."
21/03/2021 - General information
Down syndrome (DS) is the most common chromosomal abnormality in children leading to lifelong intellectual disability. Over one million people in the EU and US have DS, and its prevalence has increased in the last ten years. Thanks to significant advances in medical and social care, the life expectancy of individuals with DS has increased greatly, so that many of them reach even the age of 60-70. DS causes lifelong cognitive dysfunction, which results in important negative consequences for these individuals, their families and society. Despite the heavier social burden and the greater medical needs linked to this intellectual disability, there isn't an approved therapy for DS-related cognitive dysfunction yet. Furthermore, though there are specific cognitive screening tests designed for individuals with DS, no official guidelines have been developed to assess their cognitive deficits or their impact on quality of life of DS individuals and their families.
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
